Novo Nordisk's Wegovy pill, which is 25 milligrams of semaglutide, is the first oral glucagon-like peptide-1 receptor agonist therapy approved for weight management. In a trial, the pill taken once daily demonstrated 16.6% mean weight loss when treatment was adhered to in adult participants with obesity. One in three people experienced 20% or greater weight loss during the trial.